Latest News

IMI’s ADAPT SMART Kick-Starts 2017 by putting stakeholders at the centre

London, January 18, 2017.- ADAPT SMART’s General Assembly, held at the European Medicines Agency (EMA), agrees to focus its final year on incorporating stakeholder feedback into the development of Medicines Adaptive Pathways to Patients (MAPPs) tools and methodologies. Myeloma Patients Europe (MPE) was attending this meeting. With growing international interest and visibility in the final…

Read more

Patients and cancer experts launch a joint vision for improving cancer outcomes in Europe

A coalition of 60 patient advocates, healthcare professionals and scientists (including 3 Nobel Prize winners) from 20 European countries have come together to publish a blueprint for improving cancer outcomes and achieving better quality of life for cancer survivors throughout Europe.1 They are members of the European Cancer Concord (ECC®), an equal partnership between patients…

Read more

MPE will hold a webinar on ASH 2016 Highlights in myeloma

Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in December 2016. The talk will be given by Dr Laurent Garderet, Department of Hematology, Saint Antoine Hospital, Paris,…

Read more

Innovative Medicines Initiative (IMI) approves € 40 million project for better care of patients with haematologic malignancies

Brussels/Salamanca, January 9, 2017. The Innovative Medicines Initiative (IMI) has approved HARMONY, a project that aims to foster better access and care for patients with various hematologic malignancies (HM) with the use of big data. The project is made up of 51 partners from 11 European countries, including 7 pharmaceutical companies. Other organisations such as…

Read more

Addition of daratumumab to bortezomib and dexamethasone in patients with relapsed or refractory shows promising results in a phase III trial

At the ESMO 2016 Congress held in Copenhagen between 7th-11th October, Dr Katja Weissel, from the Haematology and Oncology Department of Medicine at University Hospital Tuebingen (Germany), presented the results of the CASTOR study, a phase III randomised controlled study of daratumumab, bortezomib and dexamethasone (DVd) compared with bortezomib and dexamethasone (Vd) in patients with…

Read more

MPE encourages EMA to review its negative recommendation for ixazomib

Myeloma Patients Europe (MPE), in close collaboration with Myeloma UK, and along with almost 30 member and non-member associations across Europe, has submitted a letter to the Committee for Human Medicinal Products (CHMP) within the European Medicines Agency (EMA) to encourage them to reconsider the negative recommendation for ixazomib, and provide information to the appeal…

Read more

February 2026

MO
TU
WE
TH
FR
SA
SU
26
27
28
29
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
1
Events for 1st February
No Events
Events for 2nd February
No Events
Events for 3rd February
No Events
Events for 4th February
No Events
Events for 5th February
No Events
Events for 6th February
No Events
Events for 7th February
No Events
Events for 8th February
No Events
Events for 9th February
No Events
Events for 10th February
No Events
Events for 11th February
No Events
Events for 12th February
No Events
Events for 13th February
No Events
Events for 14th February
No Events
Events for 15th February
No Events
Events for 16th February
No Events
Events for 17th February
No Events
Events for 18th February
No Events
Events for 19th February
No Events
Events for 20th February
No Events
Events for 21st February
No Events
Events for 22nd February
No Events
Events for 23rd February
No Events
Events for 24th February
No Events
Events for 25th February
No Events
Events for 26th February
No Events
Events for 27th February
No Events
Events for 28th February
No Events